Читать книгу Current Perspectives in Kidney Diseases - Группа авторов - Страница 24
References
Оглавление1 Clark E, Bagshaw SM: Long-term risk of sepsis among survivors of acute kidney injury. Crit Care 2014;18:103.
2 Mehta RL, Bouchard J, Soroko SB, Ikizler TA, Paganini EP, Chertow GM, et al: Sepsis as a cause and consequence of acute kidney injury: program to improve care in acute renal disease. Intensive Care Med 2011;37:241–248.
3 Dellepiane S, Marengo M, Cantaluppi V: Detrimental cross-talk between sepsis and acute kidney injury: new pathogenic mechanisms, early biomarkers and targeted therapies. Crit Care 2016;20:61.
4 Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, et al: Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012;366:2055–2064.
5 Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al: The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016;315:801–810.
6 Murugan R, Karajala-Subramanyam V, Lee M, Yende S, Kong L, Carter M, et al: Acute kidney injury in non-severe pneumonia is associated with an increased immune response and lower survival. Kidney Int 2010;77:527–535.
7 Di Giantomasso D, Morimatsu H, May CN, Bellomo R: Intrarenal blood flow distribution in hyperdynamic septic shock: effect of norepinephrine. Crit Care Med 2003;31:2509–2513.
8 Mariano F, Cantaluppi V, Stella M, Romanazzi GM, Assenzio B, Cairo M, et al: Circulating plasma factors induce tubular and glomerular alterations in septic burns patients. Crit Care 2008;12:R42.
9 Cantaluppi V, Quercia AD, Dellepiane S, Ferrario S, Camussi G, Biancone L: Interaction between systemic inflammation and renal tubular epithelial cells. Nephrol Dial Transplant 2014;29:2004–2011.
10 Peng ZY, Zhou F, Kellum JA: Cross-species validation of cell cycle arrest markers for acute kidney injury in the rat during sepsis. Intensive Care Med Exp 2016;4:12.
11 Gupta RK, Chhibber S, Harjai K: Quorum sensing signal molecules cause renal tissue inflammation through local cytokine responses in experimental UTI caused by Pseudomonas aeruginosa. Immunobiology 2013;218:181–185.
12 Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, Mira JP, et al: Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 2013;309:1154–1162.
13 Chen J, Hartono JR, John R, Bennett M, Zhou XJ, Wang Y, et al: Early interleukin 6 production by leukocytes during ischemic acute kidney injury is regulated by TLR4. Kidney Int 2011;80:504–515.
14 Solini A, Usuelli V, Fiorina P: The dark side of extracellular ATP in kidney diseases. J Am Soc Nephrol 2015;26:1007–1016.
15 Gerritsma JS, Hiemstra PS, Gerritsen AF, Prodjosudjadi W, Verweij CL, Van Es LA, et al: Regulation and production of IL-8 by human proximal tubular epithelial cells in vitro. Clin Exp Immunol 1996;103:289–294.
16 Panacek EA, Marshall JC, Albertson TE, Johnson DH, Johnson S, MacArthur RD, et al: Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 2004;32:2173–2182.
17 Husi H, Sanchez-Niño MD, Delles C, Mullen W, Vlahou A, Ortiz A, et al: A combinatorial approach of proteomics and systems biology in unravelling the mechanisms of acute kidney injury (AKI): involvement of NMDA receptor GRIN1 in murine AKI. BMC Syst Biol 2013;7:110.
18 Gaarkeuken H, Siezenga MA, Zuidwijk K, van Kooten C, Rabelink TJ, Daha MR, et al: Complement activation by tubular cells is mediated by properdin binding. Am J Physiol Renal Physiol 2008;295:F1397–F1403.
19 Heng B, Li Y, Shi L, Du X, Lai C, Cheng L, et al: A meta-analysis of the significance of granzyme B and perforin in noninvasive diagnosis of acute rejection after kidney transplantation. Transplantation 2015;99:1477–1486.
20 Sun J, Shannon M, Ando Y, Schnackenberg LK, Khan NA, Portilla D, et al: Serum metabolomic profiles from patients with acute kidney injury: a pilot study. J Chromatogr B Analyt Technol Biomed Life Sci 2012;893–894:107–113.
21 Cantaluppi V, Medica D, Mannari C, Stiaccini G, Figliolini F, Dellepiane S, et al: Endothelial progenitor cell-derived extracellular vesicles protect from complement-mediated mesangial injury in experimental anti-Thy1.1 glomerulonephritis. Nephrol Dial Transplant 2015;30:410–422.
22 Zafrani L, Gerotziafas G, Byrnes C, Hu X, Perez J, Lévi C, et al: Calpastatin controls polymicrobial sepsis by limiting procoagulant microparticle release. Am J Respir Crit Care Med 2012;185:744–755.
23 Meziani F, Delabranche X, Asfar P, Toti F: Bench-to-bedside review: circulating microparticles – a new player in sepsis? Crit Care 2010;14:236.
24 Mastronardi ML, Mostefai HA, Meziani F, Martínez MC, Asfar P, Andriantsitohaina R: Circulating microparticles from septic shock patients exert differential tissue expression of enzymes related to inflammation and oxidative stress. Crit Care Med 2011;39:1739–1748.
25 Legrand M, Dupuis C, Simon C, Gayat E, Mateo J, Lukaszewicz AC, et al: Association between systemic hemodynamics and septic acute kidney injury in critically ill patients: a retrospective observational study. Crit Care 2013;17:R278.
26 Garzotto F, Ostermann M, Martín-Langerwerf D, Sánchez-Sánchez M, Teng J, Robert R, et al: The dose response multicentre investigation on fluid assessment (DoReMIFA) in critically ill patients. Crit Care 2016;20:196.
27 Lorente L, Martín MM, Varo N, Borreguero-León JM, Solé-Violán J, Blanquer J, et al: Association between serum soluble CD40 ligand levels and mortality in patients with severe sepsis. Crit Care 2011;15:R97.
28 Rimmelé T, Payen D, Cantaluppi V, Marshall J, Gomez H, Gomez A, et al: Immune cell phenotype and function in sepsis. Shock 2016;45:282–291.
29 Barbar SD, Binquet C, Monchi M, Bruyère R, Quenot JP: Impact on mortality of the timing of renal replacement therapy in patients with severe acute kidney injury in septic shock: the IDEAL-ICU study (initiation of dialysis early versus delayed in the intensive care unit): study protocol for a randomized controlled trial. Trials 2014;15:270.
30 Bagshaw SM, Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, et al: Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes. Clin J Am Soc Nephrol 2007;2:431–439.
31 Oppert M, Engel C, Brunkhorst FM, Bogatsch H, Reinhart K, Frei U, et al: Acute renal failure in patients with severe sepsis and septic shock – a significant independent risk factor for mortality: results from the German Prevalence Study. Nephrol Dial Transplant 2008;23:904–909.
32 Hoffmann JN, Hartl WH, Deppisch R, Faist E, Jochum M, Inthorn D: Hemofiltration in human sepsis: evidence for elimination of immunomodulatory substances. Kidney Int 1995;48:1563–1570.
33 Bellomo R, Kellum JA, Gandhi CR, Pinsky MR, Ondulik B: The effect of intensive plasma water exchange by hemofiltration on hemodynamics and soluble mediators in canine endotoxemia. Am J Respir Crit Care Med 2000;161:1429–1436.
34 Gomez H, Ince C, De Backer D, Pickkers P, Payen D, Hotchkiss J, et al: A unified theory of sepsis-induced acute kidney injury: inflammation, microcirculatory dysfunction, bioenergetics, and the tubular cell adaptation to injury. Shock 2014;41:3–11.
35 Ronco C, Kellum JA, Bellomo R, House AA: Potential interventions in sepsis-related acute kidney injury. Clin J Am Soc Nephrol 2008;3:531–544.
36 Oh HJ, Shin DH, Lee MJ, Koo HM, Doh FM, Kim HR, et al: Early initiation of continuous renal replacement therapy improves patient survival in severe progressive septic acute kidney injury. J Crit Care 2012;27:743.e9–e18.
37 Chon GR, Chang JW, Huh JW, Lim CM, Koh Y, Park SK, et al: A comparison of the time from sepsis to inception of continuous renal replacement therapy versus RIFLE criteria in patients with septic acute kidney injury. Shock 2012;38:30–36.
38 Carl DE, Grossman C, Behnke M, Sessler CN, Gehr TW: Effect of timing of dialysis on mortality in critically ill, septic patients with acute renal failure. Hemodial Int 2010;14:11–17.
39 Ostermann M, Dickie H, Barrett NA: Renal replacement therapy in critically ill patients with acute kidney injury – when to start. Nephrol Dial Transplant 2012;27:2242–2248.
40 Joannidis M, Forni LG: Clinical review: timing of renal replacement therapy. Crit Care 2011;15:223.
41 Karvellas CJ, Farhat MR, Sajjad I, Mogensen SS, Leung AA, Wald R, et al: A comparison of early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury: a systematic review and meta-analysis. Crit Care 2011;15:R72.
42 Shum HP, Chan KC: Timing for initiation of continuous renal replacement therapy in patients with septic shock and acute kidney injury. Ther Apher Dial 2013;17:643.
43 Gaudry S, Hajage D, Schortgen F, Martin-Lefevre L, Pons B, Boulet E, et al: Initiation strategies for renal-replacement therapy in the intensive care unit. N Engl J Med 2016;375:122–133.
44 Kellum JA, Lameire N; KDIGO AKI Guideline Work Group: Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (part 1). Crit Care 2013;17:204.
45 Fülöp T, Pathak MB, Schmidt DW, Lengvárszky Z, Juncos JP, Lebrun CJ, et al: Volume-related weight gain and subsequent mortality in acute renal failure patients treated with continuous renal replacement therapy. ASAIO J 2010;56:333–337.
46 Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P, et al: Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 2000;356:26–30.
47 RENAL Replacement Therapy Study Investigators, Bellomo R, Cass A, Cole L, Finfer S, Gallagher M, et al: Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 2009;361:1627–1638.
48 VA/NIH Acute Renal Failure Trial Network, Palevsky PM, Zhang JH, O’Connor TZ, Chertow GM, Crowley ST, et al: Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 2008;359:7–20.
49 Joannes-Boyau O, Honoré PM, Perez P, Bagshaw SM, Grand H, Canivet JL, et al: High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial. Intensive Care Med 2013;39:1535–1546.
50 Doyle JF, Forni LG: Update on sepsis-associated acute kidney injury: emerging targeted therapies. Biologics 2016;10:149–156.
51 Prowle JR, Bellomo R: Continuous renal replacement therapy: recent advances and future research. Nat Rev Nephrol 2010;6:521–529.
52 Wald R, Friedrich JO, Bagshaw SM, Burns KE, Garg AX, Hladunewich MA, et al: Optimal mode of clearance in critically ill patients with acute kidney injury (OMAKI) – a pilot randomized controlled trial of hemofiltration versus hemodialysis: a Canadian Critical Care Trials Group project. Crit Care 2012;16:R205.
53 Fiaccadori E, Maggiore U, Parenti E, Giacosa R, Picetti E, Rotelli C, et al: Sustained low-efficiency dialysis (SLED) with prostacyclin in critically ill patients with acute renal failure. Nephrol Dial Transplant 2007;22:529–537.
54 Oudemans-van Straaten HM, Bosman RJ, Koopmans M, van der Voort PH, Wester JP, van der Spoel JI, et al: Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med 2009;37:545–552.
55 Yumoto M, Nishida O, Moriyama K, Shimomura Y, Nakamura T, Kuriyama N, et al: In vitro evaluation of high mobility group box 1 protein removal with various membranes for continuous hemofiltration. Ther Apher Dial 2011;15:385–393.
56 Honore PM, Jacobs R, Joannes-Boyau O, De Regt J, De Waele E, van Gorp V, et al: Newly designed CRRT membranes for sepsis and SIRS – a pragmatic approach for bedside intensivists summarizing the more recent advances: a systematic structured review. ASAIO J 2013;59:99–106.
57 Morgera S, Haase M, Kuss T, Vargas-Hein O, Zuckermann-Becker H, Melzer C, et al: Pilot study on the effects of high cutoff hemofiltration on the need for norepinephrine in septic patients with acute renal failure. Crit Care Med 2006;34:2099–2104.
58 Haase M, Bellomo R, Baldwin I, Haase-Fielitz A, Fealy N, Davenport P, et al: Hemodialysis membrane with a high-molecular-weight cutoff and cytokine levels in sepsis complicated by acute renal failure: a phase 1 randomized trial. Am J Kidney Dis 2007;50:296–304.
59 Borthwick EM, Hill CJ, Rabindranath KS, Maxwell AP, McAuley DF, Blackwood B: High-volume haemofiltration for sepsis in adults. Cochrane Database Syst Rev 2017;1:CD008075.
60 Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, et al: Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009;301:2445–2452.
61 Payen DM, Guilhot J, Launey Y, Lukaszewicz AC, Kaaki M, Veber B, et al: Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med 2015;41:975–984.
62 Klein DJ, Foster D, Schorr CA, Kazempour K, Walker PM, Dellinger RP: The EUPHRATES trial (evaluating the use of polymyxin B hemoperfusion in a randomized controlled trial of adults treated for endotoxemia and septic shock): study protocol for a randomized controlled trial. Trials 2014;15:218.
63 Cruz DN, de Cal M, Piccinni P, Ronco C: Polymyxin-B hemoperfusion and endotoxin removal: lessons from a review of the literature. Contrib Nephrol 2010;167:77–82.
64 Cantaluppi V, Quercia AD, Dellepiane S, Figliolini F, Medica D, De Lena M: [New mechanisms and recent insights in the pathogenesis of acute kidney injury (AKI)]. G Ital Nefrol 2012;29:535–547.
65 Kellum JA, Venkataraman R, Powner D, Elder M, Hergenroeder G, Carter M: Feasibility study of cytokine removal by hemoadsorption in brain-dead humans. Crit Care Med 2008;36:268–272.
66 Livigni S, Bertolini G, Rossi C, Ferrari F, Giardino M, Pozzato M, et al: Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: A multicenter randomised controlled clinical trial. BMJ Open 2014;4:e003536.
67 Tumlin J, Wali R, Williams W, Murray P, Tolwani AJ, Vinnikova AK, et al: Efficacy and safety of renal tubule cell therapy for acute renal failure. J Am Soc Nephrol 2008;19:1034–1040.
68 Tumlin JA, Chawla L, Tolwani AJ, Mehta R, Dillon J, Finkel KW, et al: The effect of the selective cytopheretic device on acute kidney injury outcomes in the intensive care unit: a multicenter pilot study. Semin Dial 2013;26:616–623.
69 Tsai AC, Ma T: Expansion of human mesenchymal stem cells in a microcarrier bioreactor. Methods Mol Biol 2016;1502:77–86.
70 González de Molina FJ, Ferrer R: Appropriate antibiotic dosing in severe sepsis and acute renal failure: factors to consider. Crit Care 2011;15:175.
71 Shaw AR, Chaijamorn W, Mueller BA: We underdose antibiotics in patients on CRRT. Semin Dial 2016;29:278–280.
Prof. Vincenzo Cantaluppi
SCDU Nefrologia e Trapianto Renale, Dipartimento di Medicina Traslazionale
Università del Piemonte Orientale (UPO) “A. Avogadro”
Azienda Ospedaliera Universitaria “Maggiore della Carità”
Corso Mazzini 18, IT–28100 Novara (Italy)
